Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Syndax Pharmaceuticals Inc ASH Annual Meeting Data Update Call Transcript

Dec 11, 2022 / 02:00PM GMT
Operator

Good day, everyone, and welcome to the Syndax ASH Annual Meeting Data Update Call. Today's call is being recorded.

At this time, I would like to turn the call over to Michael Metzger, Chief Executive Officer of Syndax Pharmaceuticals.

Michael A. Metzger
Syndax Pharmaceuticals, Inc. - CEO & Director

Thank you, operator, and thanks to everyone joining us this morning to review our revumenib data presented yesterday in 2 oral presentations at the 64th ASH Annual Meeting.

I want to begin by pointing out our forward-looking statements on Slide 2. Before we review the Phase I data for revumenib, our highly selective menin inhibitor and hear from 2 of our principal investigators, I would like to take a moment to outline Syndax goals for this year's ASH meeting on Slide 3. Our team is first and foremost focused on physician engagement and our disease awareness campaign at ASH.

As leaders in the menin inhibitor field, we continue to build the awareness of the benefits of using a menin inhibitor to treat mutant NPM1 and KMT2A acute

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot